GSK welcomes key agreement to support global preparedness against pandemic influenza

GlaxoSmithKlineGlaxoSmithKline (GSK) welcomes the agreement reached at the Open Ended Working Group (OEWG) coordinated by the World Health Organisation (WHO) on a Framework to support global preparedness for a future influenza pandemic. The agreement establishes the principles of an improved process for influenza virus and benefit-sharing between the WHO GISN (Global Influenza Surveillance Network) and industry.

The agreement will mean that companies supplying vaccines, antivirals and diagnostics for influenza will become key stakeholders in the WHO GISN, which tracks the development and movement of influenza viruses globally. Industry will increase its financial contribution to the GISN to enable the network's geographical expansion and support technical improvements that will accelerate the start of vaccine production, enabling industry to deliver seasonal and pandemic influenza vaccines more quickly.

Industry has also committed to provide other benefits to enable the world's poorer countries to manage the challenge of pandemic influenza. These benefits include real-time production allocations of pandemic vaccines and antivirals, which will be donated to WHO for use, especially for lower-income countries, or supplied at tiered prices, again especially for lower-income countries. In addition, manufacturers have agreed to explore, where appropriate, the establishment of local manufacture of these products in developing countries through technology transfer and licensing.

Andrew Witty, CEO of GSK, said: "This Framework agreement is a critical step in ensuring that the world, including developing countries, is able to prepare properly and equitably for any future pandemic. I applaud the leadership of the WHO. Member States and industry have demonstrated a shared commitment to addressing global needs and an ability to work together and compromise.

"GSK made a significant contribution to managing the previous H1N1 pandemic - through donation of both vaccines and antiviral medicines, and through supplying products to the developing world at tiered prices that reflect ability to pay. We are committed to playing a major role now in preparing for a future pandemic.

"The principles in the agreement strike an important balance. They ensure that there will be equitable access to vaccines and medicines - but maintain an intellectual property framework that will encourage the development of new medicines and vaccines. They also recognise that all stakeholders have their part to play. We look forward to participating in future discussions to move beyond principles and agree a full and balanced plan."

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

Most Popular Now

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...